PT - JOURNAL ARTICLE ED - , TI - Three More Drugs Judged “Breakthroughs” AID - 10.1158/2159-8290.CD-NB2013-142 DP - 2013 Nov 01 TA - Cancer Discovery PG - OF2--OF2 VI - 3 IP - 11 4099 - http://cancerdiscovery.aacrjournals.org/content/3/11/OF2.short 4100 - http://cancerdiscovery.aacrjournals.org/content/3/11/OF2.full SO - CANCER DISCOVERY2013 Nov 01; 3 AB - The U.S. Food and Drug Administration has granted Breakthrough Therapy status to volasertib, entinostat, and alectinib, which are under development for the treatment of acute myeloid leukemia, estrogen receptor–positive breast cancer, and non–small cell lung cancer, respectively.